Krilogy Financial LLC Takes $771,000 Position in BioMarin Pharmaceutical Inc. $BMRN

Krilogy Financial LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 14,594 shares of the biotechnology company’s stock, valued at approximately $771,000.

Other large investors have also recently bought and sold shares of the company. Quent Capital LLC bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $28,000. Smartleaf Asset Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 360 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of BioMarin Pharmaceutical by 480.2% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 874 shares in the last quarter. Employees Retirement System of Texas bought a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $58,000. Finally, Jones Financial Companies Lllp lifted its holdings in BioMarin Pharmaceutical by 88.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 656 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $59.87 on Friday. The firm’s 50-day moving average is $57.25 and its 200-day moving average is $55.98. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 4.83. The company has a market cap of $11.50 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 0.65 and a beta of 0.26.

Analyst Ratings Changes

Several brokerages have commented on BMRN. HC Wainwright increased their price target on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, December 22nd. Truist Financial raised their target price on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Barclays began coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, January 28th. They set an “overweight” rating and a $80.00 target price for the company. Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Finally, Wolfe Research reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.29.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.